核治療薬の世界市場レポート 2025年

核治療薬の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR14.7％で38億6,000万米ドルに成長します。予測期間の成長は、個別化医療へのシフト、ヘルスケアインフラの改善に対する需要の高まり、高齢者人口の増加、画像診断処置の増加、個別化ケア提供の台頭などに起因しています。予測期間における主な動向としては、ナノ粒子ベースの送達システム、放射性核種治療の進歩、ハイブリッド画像システム、放射性医薬品の製造とアルファ線放出放射性医薬品の開発、機械学習と人工知能の統合などが挙げられます。

がん罹患率の上昇が核治療薬市場の成長を牽引すると予想されます。異常細胞の制御不能な増殖と拡散を特徴とするがんは、発見と診断の改善、ライフスタイルの選択、環境暴露、遺伝的素因などの要因により、より蔓延しつつあります。核治療薬は、腫瘍の縮小、症状の緩和、患者のQOLの向上に役立つ標的を絞った効果的な治療法を提供することで、がん治療において重要な役割を果たしています。例えば、2024年2月、スイスに本部を置く国連機関である世界保健機関（WHO）は、2050年までに新たに診断されるがん患者は3,500万人を超え、2022年の推定2,000万人から77％増加すると予測しました。その結果、がん罹患率の増加が核治療薬市場の拡大に拍車をかけています。

核治療薬市場の主要企業は、競争力を強化するために戦略的パートナーシップを結ぶことが増えています。こうした提携は、研究開発能力を強化し、新しい治療法の商業化を加速し、共有するリソースや専門知識を活用して革新的な治療法へのアクセスを改善する上で極めて重要です。例えば、2022年7月、ドイツを拠点とするソフトウェア会社DeepCは、核医学診断の進歩のため、米国を拠点とするAIソリューション・プロバイダーであるPAIREと提携しました。この提携により、PET/CTスキャンの解釈を強化するDeepCのdeepcOSプラットフォームにPAIREのAIソリューションであるPionusを統合することで、核医学診断の精度と効率の向上を目指します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界核治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の核治療薬市場：成長率分析
• 世界の核治療薬市場の実績：規模と成長, 2019-2024
• 世界の核治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界核治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の核治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラジウム223
• ルテチウム177
• ヨウ素131
• その他のタイプ
• 世界の核治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター（ASC）
• がん調査機関
• 世界の核治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 甲状腺
• 骨転移
• リンパ腫
• その他の用途
• 世界の核治療薬市場ラジウム223の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前立腺がんの適応症
• 作用機序
• 剤形
• 世界の核治療薬市場ルテチウム177の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経内分泌腫瘍への応用
• 治療プロトコル
• 併用療法
• 世界の核治療薬市場ヨウ素131の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 甲状腺がんにおける使用
• 用法・用量
• 安全性と有効性
• 世界の核治療薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 追加の治療用同位元素
• 新しい治療法
• 研究開発動向

第7章 地域別・国別分析

• 世界の核治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の核治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 核治療薬市場：競合情勢
• 核治療薬市場：企業プロファイル
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • Ipsen S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Jubilant DraxImage Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Mallinckrodt Pharmaceuticals PLC
• The Bracco Group
• Lantheus Medical Imaging Inc.
• Piramal Group
• Curium Pharmaceuticals
• Yantai Dongcheng Pharmaceutical Group Co. Ltd.
• Eckert & Ziegler
• Telix Pharmaceuticals Limited
• International Isotopes inc.
• Orano SA
• Q BioMed Inc.
• Molecular Targeting Technologies Inc
• Medi-Radiopharma Co. Ltd.
• Actinium Pharmaceuticals
• Fusion Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 核治療薬市場2029：新たな機会を提供する国
• 核治療薬市場2029：新たな機会を提供するセグメント
• 核治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Therapeutic nuclear drugs are medications that use radioactive materials to target and treat diseases, primarily cancer. These drugs employ targeted radiopharmaceuticals that bind to cancer cells and deliver a therapeutic dose of radiation directly to them, aiming to destroy the cancerous cells while minimizing damage to surrounding healthy tissue.

The main types of therapeutic nuclear drugs include radium-223, lutetium-177, iodine-131, and others. Radium-223, for example, is used mainly to treat prostate cancer that has metastasized to the bones. These drugs are distributed through various channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and are utilized in applications like treating thyroid cancer, bone metastases, lymphoma, and other conditions.

The therapeutic nuclear drugs market research report is one of a series of new reports from The Business Research Company that provides therapeutic nuclear drugs market statistics, including the therapeutic nuclear drugs industry global market size, regional shares, competitors with a therapeutic nuclear drugs market share, detailed therapeutic nuclear drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the therapeutic nuclear drugs industry. This therapeutic nuclear drug research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic nuclear drug market size has grown rapidly in recent years. It will grow from $1.94 $ billion in 2024 to $2.23 $ billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing regulatory approvals, increasing use of patient-specific information, improving dosimetry techniques, increasing awareness of nuclear medicines and increasing investment in research and development activities.

The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $3.86 $ billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to the shift towards personalized medicine, the rising demand for healthcare infrastructure improvements, the growing geriatric population, the growing number of diagnostic imaging procedures, and the rise of personalized care delivery. Major trends in the forecast period include nanoparticle-based delivery systems, advancements in radionuclide therapy, hybrid imaging systems, radiopharmaceutical manufacturing and development of alpha-emitting radiopharmaceuticals, and integration of machine learning and artificial intelligence.

The rising prevalence of cancer is expected to drive the growth of the therapeutic nuclear drug market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, is becoming more prevalent due to factors such as improved detection and diagnosis, lifestyle choices, environmental exposures, and genetic predisposition. Therapeutic nuclear drugs play a crucial role in cancer treatment by offering targeted, effective therapies that help reduce tumor size, alleviate symptoms, and improve patients' quality of life. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based UN agency, projected that over 35 million new cancer cases will be diagnosed by 2050, marking a 77% increase from the estimated 20 million cases in 2022. As a result, the growing prevalence of cancer is fueling the expansion of the therapeutic nuclear drug market.

Major companies in the therapeutic nuclear drug market are increasingly forming strategic partnerships to strengthen their competitive position. These collaborations are crucial for enhancing research and development capabilities, speeding up the commercialization of new therapies, and improving access to innovative treatments by leveraging shared resources and expertise. For example, in July 2022, DeepC, a Germany-based software company, partnered with PAIRE, a U.S.-based AI solutions provider, to advance nuclear medicine diagnostics. Through this partnership, they aim to improve the precision and efficiency of nuclear medicine diagnostics by integrating PAIRE's AI solution, Pionus, into DeepC's deepcOS platform, which enhances the interpretation of PET/CT scans.

In May 2024, Telix Pharmaceuticals Limited, an Australian biotechnology company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix's therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which targets bone metastases and osteosarcoma. QSAM Biosciences, a US-based biotech firm, specializes in developing next-generation nuclear therapeutic medicines.

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

North America was the largest region in the therapeutic nuclear drug market in 2023. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the therapeutic nuclear drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Therapeutic Nuclear Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on therapeutic nuclear drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for therapeutic nuclear drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The therapeutic nuclear drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Radium-223; Lutetium-177; Iodine-131; Other Types
• 2) By Distribution Channel: Hospitals; Ambulatory Surgical Centers (ASCs); Cancer Research Institutes
• 3) By Application: Thyroid; Bone Metastasis; Lymphoma; Other Applications
• Subsegments:
• 1) Radium-223: Indications for prostate cancer; Mechanism of action; Dosage forms
• 2) Lutetium-177: Applications in neuroendocrine tumors; Treatment protocols; Combination therapies
• 3) Iodine-131: Use in thyroid cancer; Dosage and administration; Safety and efficacy
• 4) Other Types: Additional therapeutic isotopes; Emerging treatments; Research and development trends
• Companies Mentioned: Bayer AG; Novartis International AG; Siemens Healthineers AG; Ipsen S.A.; Jubilant DraxImage Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Therapeutic Nuclear Drug Market Characteristics

3. Therapeutic Nuclear Drug Market Trends And Strategies

4. Therapeutic Nuclear Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Therapeutic Nuclear Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Therapeutic Nuclear Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Therapeutic Nuclear Drug Market Growth Rate Analysis
• 5.4. Global Therapeutic Nuclear Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Therapeutic Nuclear Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Therapeutic Nuclear Drug Total Addressable Market (TAM)

6. Therapeutic Nuclear Drug Market Segmentation

• 6.1. Global Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radium-223
• Lutetium-177
• Iodine-131
• Other Types
• 6.2. Global Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Cancer Research Institutes
• 6.3. Global Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thyroid
• Bone Metastasis
• Lymphoma
• Other Applications
• 6.4. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Radium-223, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prostate Cancer Indications
• Mechanism of Action
• Dosage Forms
• 6.5. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Lutetium-177, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Applications in Neuroendocrine Tumors
• Treatment Protocols
• Combination Therapies
• 6.6. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Iodine-131, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Use in Thyroid Cancer
• Dosage and Administration
• Safety and Efficacy
• 6.7. Global Therapeutic Nuclear Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Additional Therapeutic Isotopes
• Emerging Treatments
• Research and Development Trends

7. Therapeutic Nuclear Drug Market Regional And Country Analysis

• 7.1. Global Therapeutic Nuclear Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Therapeutic Nuclear Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Therapeutic Nuclear Drug Market

• 8.1. Asia-Pacific Therapeutic Nuclear Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Therapeutic Nuclear Drug Market

• 9.1. China Therapeutic Nuclear Drug Market Overview
• 9.2. China Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Therapeutic Nuclear Drug Market

• 10.1. India Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Therapeutic Nuclear Drug Market

• 11.1. Japan Therapeutic Nuclear Drug Market Overview
• 11.2. Japan Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Therapeutic Nuclear Drug Market

• 12.1. Australia Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Therapeutic Nuclear Drug Market

• 13.1. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Therapeutic Nuclear Drug Market

• 14.1. South Korea Therapeutic Nuclear Drug Market Overview
• 14.2. South Korea Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Therapeutic Nuclear Drug Market

• 15.1. Western Europe Therapeutic Nuclear Drug Market Overview
• 15.2. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Therapeutic Nuclear Drug Market

• 16.1. UK Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Therapeutic Nuclear Drug Market

• 17.1. Germany Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Therapeutic Nuclear Drug Market

• 18.1. France Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Therapeutic Nuclear Drug Market

• 19.1. Italy Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Therapeutic Nuclear Drug Market

• 20.1. Spain Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Therapeutic Nuclear Drug Market

• 21.1. Eastern Europe Therapeutic Nuclear Drug Market Overview
• 21.2. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Therapeutic Nuclear Drug Market

• 22.1. Russia Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Therapeutic Nuclear Drug Market

• 23.1. North America Therapeutic Nuclear Drug Market Overview
• 23.2. North America Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Therapeutic Nuclear Drug Market

• 24.1. USA Therapeutic Nuclear Drug Market Overview
• 24.2. USA Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Therapeutic Nuclear Drug Market

• 25.1. Canada Therapeutic Nuclear Drug Market Overview
• 25.2. Canada Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Therapeutic Nuclear Drug Market

• 26.1. South America Therapeutic Nuclear Drug Market Overview
• 26.2. South America Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Therapeutic Nuclear Drug Market

• 27.1. Brazil Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Therapeutic Nuclear Drug Market

• 28.1. Middle East Therapeutic Nuclear Drug Market Overview
• 28.2. Middle East Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Therapeutic Nuclear Drug Market

• 29.1. Africa Therapeutic Nuclear Drug Market Overview
• 29.2. Africa Therapeutic Nuclear Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Therapeutic Nuclear Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Therapeutic Nuclear Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Therapeutic Nuclear Drug Market Competitive Landscape And Company Profiles

• 30.1. Therapeutic Nuclear Drug Market Competitive Landscape
• 30.2. Therapeutic Nuclear Drug Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Ipsen S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Jubilant DraxImage Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Therapeutic Nuclear Drug Market Other Major And Innovative Companies

• 31.1. Mallinckrodt Pharmaceuticals PLC
• 31.2. The Bracco Group
• 31.3. Lantheus Medical Imaging Inc.
• 31.4. Piramal Group
• 31.5. Curium Pharmaceuticals
• 31.6. Yantai Dongcheng Pharmaceutical Group Co. Ltd.
• 31.7. Eckert & Ziegler
• 31.8. Telix Pharmaceuticals Limited
• 31.9. International Isotopes inc.
• 31.10. Orano SA
• 31.11. Q BioMed Inc.
• 31.12. Molecular Targeting Technologies Inc
• 31.13. Medi-Radiopharma Co. Ltd.
• 31.14. Actinium Pharmaceuticals
• 31.15. Fusion Pharmaceuticals

32. Global Therapeutic Nuclear Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Therapeutic Nuclear Drug Market

34. Recent Developments In The Therapeutic Nuclear Drug Market

35. Therapeutic Nuclear Drug Market High Potential Countries, Segments and Strategies

• 35.1 Therapeutic Nuclear Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Therapeutic Nuclear Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Therapeutic Nuclear Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer